Pottegård A - Search Results

1

Author response: Use of β2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease.

Pottegård A, Hopfner F, Wod M, Höglinger GU, Blaabjerg M, Rösler TW, Kuhlenbäumer G, Christensen K, Deuschl G. Pottegård A, et al. Neurology. 2020 May 19;94(20):899. doi: 10.1212/WNL.0000000000009448. Neurology. 2020. PMID: 32423987 No abstract available.

2

Early Discontinuation of Metformin in Individuals Treated with Inhibitors of Transporters of Metformin.

Stage TB, Lee MP, Hallas J, Christensen MM, Brøsen K, Christensen K, Gagne JJ, Pottegård A. Stage TB, et al. Among authors: pottegard a. Basic Clin Pharmacol Toxicol. 2016 Jun;118(6):487-95. doi: 10.1111/bcpt.12579. Epub 2016 Apr 25. Basic Clin Pharmacol Toxicol. 2016. PMID: 27128732 Free article.

3

Drug use among complete responders, partial responders and non-responders in a longitudinal survey of nonagenarians: analysis of prescription register data.

Wastesson JW, Rasmussen L, Oksuzyan A, Hallas J, Christensen K, Pottegård A. Wastesson JW, et al. Among authors: pottegard a. Pharmacoepidemiol Drug Saf. 2017 Feb;26(2):152-161. doi: 10.1002/pds.4120. Epub 2016 Oct 28. Pharmacoepidemiol Drug Saf. 2017. PMID: 27790805

4

Use of β2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease.

Hopfner F, Wod M, Höglinger GU, Blaabjerg M, Rösler TW, Kuhlenbäumer G, Christensen K, Deuschl G, Pottegård A. Hopfner F, et al. Among authors: pottegard a. Neurology. 2019 Jul 9;93(2):e135-e142. doi: 10.1212/WNL.0000000000007694. Epub 2019 May 24. Neurology. 2019. PMID: 31127070

5

β-adrenoreceptors and the risk of Parkinson's disease.

Hopfner F, Höglinger GU, Kuhlenbäumer G, Pottegård A, Wod M, Christensen K, Tanner CM, Deuschl G. Hopfner F, et al. Among authors: pottegard a. Lancet Neurol. 2020 Mar;19(3):247-254. doi: 10.1016/S1474-4422(19)30400-4. Epub 2020 Jan 27. Lancet Neurol. 2020. PMID: 31999942 Review.

6

Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease.

Simmering JE, Welsh MJ, Liu L, Narayanan NS, Pottegård A. Simmering JE, et al. Among authors: pottegard a. JAMA Neurol. 2021 Apr 1;78(4):407-413. doi: 10.1001/jamaneurol.2020.5157. JAMA Neurol. 2021. PMID: 33523098 Free PMC article.

7

Use of azathioprine for non-thymoma myasthenia and risk of cancer: a nationwide case-control study in Denmark.

Pedersen EG, Pottegård A, Hallas J, Friis S, Hansen K, Jensen PE, Gaist D. Pedersen EG, et al. Among authors: pottegard a. Eur J Neurol. 2013 Jun;20(6):942-8. doi: 10.1111/ene.12108. Epub 2013 Feb 28. Eur J Neurol. 2013. PMID: 23448676

8

Risk of non-melanoma skin cancer in myasthenia patients treated with azathioprine.

Pedersen EG, Pottegård A, Hallas J, Friis S, Hansen K, Jensen PE, Gaist D. Pedersen EG, et al. Among authors: pottegard a. Eur J Neurol. 2014 Mar;21(3):454-8. doi: 10.1111/ene.12329. Epub 2013 Dec 16. Eur J Neurol. 2014. PMID: 24330255

9

Myasthenia and risk of cancer: a population-based case-control study.

Pedersen EG, Pottegård A, Hallas J, Friis S, Hansen K, Jensen PE, Gaist D. Pedersen EG, et al. Among authors: pottegard a. Eur J Neurol. 2014 May;21(5):773-8. doi: 10.1111/ene.12383. Epub 2014 Feb 26. Eur J Neurol. 2014. PMID: 24571170

10

Discontinuation of therapy among COPD patients who experience an improvement in exacerbation status.

Reilev M, Kristensen KB, Søndergaard J, Henriksen DP, Thompson W, Pottegård A. Reilev M, et al. Among authors: pottegard a. Eur J Clin Pharmacol. 2019 Jul;75(7):1025-1032. doi: 10.1007/s00228-019-02667-4. Epub 2019 Mar 22. Eur J Clin Pharmacol. 2019. PMID: 30903196

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

388 results

Search Page

Filters